 |
|
|
|
 |
|
|
|
| Article 1 to 8 out of 8 concerning BioCurex, Inc.
|
-
European Patent Office Grants Patent for BioCurex's RECAF Blood Tests
(03/28/2008)
BioCurex Inc. announced that the European Patent Office (EPO) has granted the Company's patent claims for cancer diagnostic serum tests based on the RECAF marker. A ``continuation in part'' patent application (also referred to as a ``divisional'') ...
-
BioCurex Licenses RECAF Technology to Inverness Medical Innovations
(01/11/2008)
BioCurex and Inverness Medical Innovations have announced a licensing agreement for BioCurex's RECAF material and technology. RECAF (the receptor for alpha-fetoprotein) is a wide-spectrum marker present in malignant cancer cells and absent in most ...
-
Dr. Stewart Sell Wins ISOBM-Abbott Award
(09/27/2007)
Dr. Stewart Sell, a member of BioCurex's Scientific Advisory Board, has been awarded the prestigious ISOBM-Abbott award for his lifetime achievements in cancer research, immunology, developmental biology, and stem cell research. Dr. Sell's ...
-
BioCurex Begins Development of Unique 'POINT-OF-CARE' Test For Cancer
(02/19/2007)
BioCurex Inc. announced that is has started development of a 'point-of-care' RECAF test which would be available for use at the doctor's office rather than in a laboratory setting. During the past two quarters, the Company has been engaged in ...
-
BioCurex Enters Collaboration Agreement With Largest Cancer Research Center in Russia
(12/11/2006)
BioCurex Inc. announced that it has signed a collaboration agreement with the Blokhin Cancer Research Center in Moscow, Russia, for further development and evaluation of its RECAF(TM) technology. This new phase of the BioCurex/Blokhin collaboration ...
-
Independent Results Support the Use of BioCurex Technology for Gastric Cancer
(10/19/2006)
BioCurex Inc. announced that a group of scientists led by Dr. So Tsuboi from the Shigei Medical Research Hospital, Japan, have published results on the expression of the receptor for AFP (RECAF) in normal, benign and malignant stomach tissue. The ...
-
BioCurex Signs Collaboration Agreement with Goshen Cancer Center
(05/24/2005)
BioCurex Inc. announced that it has initiated a collaboration with the Center for Cancer Care in Goshen, Indiana, for developing and evaluating its RECAF(tm) technology. The collaboration with Biocurex and the Center for Cancer Care is long term and ...
-
Abbott and Biocurex enter into agreement for RECAF(TM) cancer technology
(04/04/2005)
Abbott and BioCurex announced they have entered into a licensing agreement for BioCurex's RECAF(TM) material and technology. The receptor for alpha-fetoprotein, RECAF has emerged as a potential biomarker that may be useful in the development of new ...
Additional information
BioCurex, Inc.
Richmond, BC, Canada
Company
|
|
|
|
Top
